We are live on ! Find out more
TARS icon

Tarsus Pharmaceuticals
TARS

43 hedge funds and large institutions have $294M invested in Tarsus Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

6% more capital invested

Capital invested by funds: $277M → $294M (+$16.9M)

0.65% more ownership

Funds ownership: 62.56% → 63.22% (+0.65%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less funds holding

Funds holding: 44 → 43 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
43
Holders Change
-1
Holders Change %
-2.27%
% of All Funds
0.66%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
17
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$4.46M
2
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$1.1M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$785K
4
TCM
TimesSquare Capital Management
New York
+$261K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$234K

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$1.08M
2
JGC
J. Goldman & Co
New York
-$478K
3
Morgan Stanley
Morgan Stanley
New York
-$450K
4
VEA
Virtus ETF Advisers
New York
-$129K
5
Invesco
Invesco
Georgia
-$122K
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
1
Vivo Capital
California
$67.2M – – –
RI
2
RTW Investments
New York
$45.3M – – –
FM
3
Frazier Management
Washington
$31.9M – – –
CAM
4
Cormorant Asset Management
Massachusetts
$31.6M -$1.08M -41,500 -3%
PA
5
Perceptive Advisors
New York
$29.2M – – –
TCM
6
TimesSquare Capital Management
New York
$14.9M +$261K +10,020 +2%
CAC
7
Cowen and Company
New York
$11.6M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$10.3M +$785K +30,200 +7%
BlackRock
9
BlackRock
New York
$10.1M +$191K +7,338 +2%
JG
10
Jefferies Group
New York
$9.52M – – –
SCV
11
Sands Capital Ventures
Virginia
$5.85M – – –
Ensign Peak Advisors
12
Ensign Peak Advisors
Utah
$5.46M +$1.1M +42,451 +21%
JP Morgan Chase
13
JP Morgan Chase
New York
$3.93M +$4.46M +171,499 +5,298%
GTC
14
Ghost Tree Capital
New York
$3.83M – – –
State Street
15
State Street
Massachusetts
$2.92M +$76.4K +2,940 +2%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.83M +$55K +2,117 +2%
Northern Trust
17
Northern Trust
Illinois
$1.61M -$58K -2,230 -3%
Charles Schwab
18
Charles Schwab
California
$1.06M +$10.8K +415 +0.9%
SG Americas Securities
19
SG Americas Securities
New York
$997K -$50K -1,923 -4%
Goldman Sachs
20
Goldman Sachs
New York
$632K +$42.2K +1,623 +6%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$569K +$19.8K +763 +3%
N
22
Nuveen
North Carolina
$565K – – –
Invesco
23
Invesco
Georgia
$538K -$122K -4,710 -16%
Allspring Global Investments
24
Allspring Global Investments
North Carolina
$289K +$335K +12,885 New
Morgan Stanley
25
Morgan Stanley
New York
$253K -$450K -17,292 -61%
1
2

TARS Hedge Fund Activity: Q4 2021 in Review

43 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q4 2021, worth a combined $294M — up 6.1% from $277M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of TARS and 2 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 17 added.

The largest buyer was JP Morgan Chase, adding an estimated $4.46M. The largest seller was Cormorant Asset Management, cutting an estimated $1.08M.

  • 43 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q4 2021, down from 44 in Q3 2021.
  • Funds reported $294M of Tarsus Pharmaceuticals stock for Q4 2021, up 6.1% quarter-over-quarter.
  • 2 funds opened new Tarsus Pharmaceuticals positions in Q4 2021 and 3 closed out, a net change of -1 holder.
  • The largest Tarsus Pharmaceuticals buyer in Q4 2021 was JP Morgan Chase, an estimated $4.46M added.
  • The largest Tarsus Pharmaceuticals seller in Q4 2021 was Cormorant Asset Management, an estimated $1.08M sold.

Based on aggregated 13F filings for Q4 2021.